All In Biotech

NDA 022249 · Cephalon

Treanda

Bendamustine Hydrochloride · Intravenous

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Oct 25, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Mar 20, 2008

Approved uses

1

Original approval plus efficacy supplements

Registered trials

426

81 Phase 3, 51 recruiting

FAERS reports

11,430

9,922 serious, 2,006 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 31, 2022.

TREANDA is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (CLL) TREANDA ® is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established. 1.2 Non-Hodgkin Lymphoma (NHL) TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Mechanism: Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • TREANDA · BENDAMUSTINE HYDROCHLORIDE 180MG/2ML (90MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • TREANDA · BENDAMUSTINE HYDROCHLORIDE 25MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
  • TREANDA · BENDAMUSTINE HYDROCHLORIDE 45MG/0.5ML (90MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • TREANDA · BENDAMUSTINE HYDROCHLORIDE 100MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Bendamustine" as an intervention, any sponsor and status, largest first.

All 426 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,082
  • pyrexia842
  • disease progression569
  • febrile neutropenia522
  • rash516
  • neutropenia487
  • pneumonia458
  • drug ineffective438
  • platelet count decreased435
  • neutrophil count decreased418
  • product use in unapproved indication411
  • covid-19406

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200856
2009180
2010293
2011278
20121,407
2013512
2014473
2015628
2016554
2017534
2018683
2019640
2020654
2021752
20221,463
20231,034
2024755
2025301
2026233

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Jul 23, 2026

    Treanda, Injection, Solution, 25 mg/5 mL, 1 vial, Single-Dose in 1 carton (NDC 63459-390-08). A business decision has been made to discontinue manufacture of the drug.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Treanda (Bendamustine HCl)

2024 spending

$1.6M

Beneficiaries

50

213 claims

Per beneficiary

$31,188

$2,207.79 per unit

View as table
YearSpending
2020$1,622,385
2021$1,907,188
2022$2,101,803
2023$1,464,634
2024$1,559,402

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 385 on PubMed

Sponsor: Cephalon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.